
B



| D | Total \# <br> patients (\%) | \# HER2A (\%) | \# non-HER2A (\%) | Fisher's exact <br> test, p-value | Activating HER2 mutations (\# tumors) |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Breast | $21(3.1)$ | $4(4.4)$ | $17(2.9)$ | 0.51 | G309A (1), S310F (1), L755S (3), D769H <br> $(1)$, D769Y (2), V777L (1), V842I (1) |
| Gastric | $9(3.8)$ | $0(0)$ | $9(4.1)$ | 1.00 | S310F (2), V842I (1) |
| Bladder | $13(8.6)$ | $2(28.6)$ | $11(7.6)$ | 0.11 | S310F (4), L755S (1), T862A (1) |
| Lung Adenocarc. | $2(0.5)$ | $0(0)$ | $2(0.5)$ | 1.00 | S310F (1) |
| Lung Sq. cell carc. | $4(1.2)$ | $0(0)$ | $4(1.3)$ | 1.00 | 1.00 |
| Ovary | $1(0.4)$ | $0(0)$ | $1(0.4)$ | 0.19 | V842I (1) |
| Colon | $7(4.1)$ | $1(20)$ | $6(3.6)$ | 1.00 | S310F (1), V777L (1) |
| Head \& Neck | $2(0.6)$ | $0(0)$ | $2(0.6)$ | 1.00 | S310F (2) |
| Cervix | $3(3.5)$ | $0(0)$ | $3(3.6)$ | $0(0)$ | 1.00 |
| Uterine | $0(0)$ | $0(0)$ | $27(8.2)$ |  |  |
| Endometrium | $27(7.9)$ | $0(0)$ |  |  |  |

